Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4500362 | 1.00 | CHRM2 (0.46) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL596961 | 1.00 | CHRM2 (0.46) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL22103542 | 1.00 | CHRM2 (0.46) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL25602753 | 1.00 | CHRM2 (0.46) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL31621964 | 1.00 | CHRM2 (0.46) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL6256125 | 1.00 | CHRM2 (0.46) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL1144485 | 1.00 | CHRM2 (0.46) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL596960 | 0.98 | CHRM2 (0.44) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL29424947 | 0.98 | CHRM2 (0.44) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL596962 | 0.98 | CHRM2 (0.44) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452461-B1 | PIPERIDINES AS MENIN INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20010018422-A1 | Dolastatin 15 derivatives | BASF AKTIENGESELLSCHAFT | 2001-08-30 | — | — | US | disclosed |
| EP-1093460-A1 | DOLASTATIN 15 DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-25 | — | — | EP | disclosed |
| WO-2000002906-A1 | DOLASTATIN 15 DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2000-01-20 | — | — | WO | disclosed |
| US-5985837-A | CELL GROWTH INHIBITOR PEPTIDES; TREATING CANCER IN A MAMMAL | BASF AKTIENGESELLSCHAFT (DE) | 1999-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018422-A1 | Dolastatin 15 derivatives | SLCO2B1, SLCO2A1, DDOST | CHRM2 4802/4885CHRM4 4823/4885CHRM3 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.